Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scott_jiminez who wrote (1958)	11/6/2000 9:40:01 AM
From: Biomaven	Read Replies (1) of 52153

<<HDI>> I would feel safe in assume they've established a cost effective mechanism for reimbursement. I am unaware if this mechanism will translate into the US health care system. It doesn't. Getting good reimbursement in the US is a long and tortuous process, with obtaining a HCFA reimbursement code as a key initial hurdle. In general, adoption rates for this sort of device are agonizingly slow, even with compelling cost-effectiveness arguments and a strong marketing partner. There are often perverse incentives in the US healthcare system - sometimes cheaper and more efficient means less for doctors and hospitals... Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next